ARCT - NASDAQ
Arcturus Therapeutics Holdings Inc.
$7.60
+0.80%Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
At a Glance
Live Snapshotarct
Cash at End of Period
Last Annual Value
232.79M
3-Year CAGR
-16%
5-Year CAGR
-13%
10-Year CAGR
30%
Arcturus Therapeutics Holdings Inc. Competitors Analysis of Cash at End of Period
| Company | Cash at End of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT | 232.79M | -12.6% | -9.0% | 58.7% | |
 Humacyte, Inc. NASDAQ:HUMA | 50.85M | -14.2% | -25.2% | N/A | |
 Atea Pharmaceuticals, Inc. NASDAQ:AVIR | 95.71M | -12.7% | -34.0% | N/A | |
 Foghorn Therapeutics Inc. NASDAQ:FHTX | 84.13M | 0.8% | -3.9% | N/A | |
 Absci Corporation NASDAQ:ABSI | 21.08M | -38.3% | -40.4% | N/A | |
 Compass Therapeutics, Inc. NASDAQ:CMPX | 31.21M | 8.8% | -26.4% | N/A | |
 Corvus Pharmaceuticals, Inc. NASDAQ:CRVS | 4.58M | -28.7% | -40.9% | -1.0% | |
 Gossamer Bio, Inc. NASDAQ:GOSS | 37.73M | 5.5% | -27.1% | 90.5% | |
 KalVista Pharmaceuticals, Inc. NASDAQ:KALV | 229.34M | 59.8% | 35.3% | 26.6% | |
 Monopar Therapeutics Inc. NASDAQ:MNPR | 61.83B | 1941.6% | 397.4% | 171.2% | |
 REGENXBIO Inc. NASDAQ:RGNX | 36.50M | -0.1% | -36.3% | 3.9% |
Arcturus Therapeutics Holdings Inc. Fair Value Envelope
Related Guides
Continue your ARCT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.